An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

NCT00171223 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

532

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG: STI571

Sponsor

Novartis Pharmaceuticals